Proteolysis-targeting chimeras (PROTACs) are rapidly emerging as a potential therapeutic
strategy for cancer therapy by inducing the degradation of tumor-overexpressing oncogenic …

Proteolysis-targeting chimera (PROTAC) technology represents a novel and promising
modality for targeted protein degradation with transformative implications for the clinical …

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for
targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly …

Curing malignant carcinomas is a grand ambition in the development of human health. Over
the past decades, targeted therapies have become one of the most successful ways of …

Proteolysis Targeting Chimeras (PROTACs), an emerging therapeutic entity designed to
degrade target proteins by hijacking the ubiquitin–proteasome system, have the potential to …

Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention
over the last 10 years, representing a burgeoning therapeutic approach with the potential to …

Abstract PROteolysis TArgeting Chimeras (PROTACs) offer new opportunities in modern
medicine by targeting proteins that are intractable to classic inhibitors. Heterobifunctional in …

Unsatisfactory physicochemical properties of macromolecular drugs seriously hinder their
application in tumor immunotherapy. However, these problems can be effectively solved by …

Proteolysis-targeting chimeras (PROTACs) are small molecules that specifically link E3
ubiquitin ligases to proteins of interest to mediate targeted ubiquitination and degradation …

There are several challenges towards the development and clinical use of small molecule
inhibitors, which are currently the main type of targeted therapies towards intracellular …